A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 [axitinib] At Single Doses of 5 mg, 7 mg And 10 mg, And At Multiple Doses.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jan 2019 Results characterizing the physiological and molecular characteristics driving variability in axitinib AUCSS using physiologically based pharmacokinetic modeling using data from Pfizer trials (A4061019, A406010, A4061022, A4061036, A4061044, A4061055, A406105) published in the Journal of Clinical Pharmacology
28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
30 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com